Loading...

Terkeltaub, Robert Dr.

TitleProfessor
InstitutionUniversity of California San Diego
DepartmentMedicine
Address9500 Gilman Drive #9111-K
La Jolla CA 92093
Phone858-552-8585
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    McGill University, Montreal, CanadaMD1976Medicine
    McGill University, Montreal, CanadaDCS1972Biology

    Collapse Overview 
    Collapse Overview
    Research Interests
    Cartilage nucleotide metabolism and disease; the regulation of proinflammatory cytokine expression in macrophages.


    Collapse Research 
    Collapse Research Activities and Funding
    Rheumatic Diseases Research Training Grant
    NIH/NIAMS T32AR064194May 9, 2013 - Apr 30, 2019
    Role: Principal Investigator
    Innate Inflammation in Osteoarthritis
    VA I01BX001660Apr 1, 2012 - Mar 31, 2021
    Role: Principal Investigator
    Transglutaminase 2 in Arterial Calcification and Atherosclerosis
    NIH/NHLBI R01HL087252May 15, 2008 - Dec 31, 2012
    Role: Principal Investigator
    Chondrocyte S100/Calgranulins and RAGE in Osteoarthritis
    NIH/NIAMS R01AR054135Jun 1, 2006 - May 31, 2010
    Role: Principal Investigator
    ANK and Joint Ankylosis in Spondylitis
    NIH/NIAMS R01AR049366Jan 1, 2005 - Nov 30, 2008
    Role: Principal Investigator
    Molecular Mechanisms in Arterial Calcification
    NIH/NHLBI R01HL077360Jul 1, 2004 - Jun 30, 2014
    Role: Principal Investigator
    PTHRP 1 to 173 IN CHONDROCYTES
    NIH/NIAMS R01AR047347Apr 6, 2001 - Jan 31, 2006
    Role: Principal Investigator
    MULTIPURPOSE ARTHRITIS &MUSCULOSKELETAL DISEASE CENTER
    NIH/NIAMS P60AR040770Aug 1, 1991 - Feb 28, 2002
    Role: Co-Investigator
    Studies of Joint Aging and Osteoarthritis
    NIH P01AG007996Dec 1, 1988 - Apr 30, 2017
    Role: Co-Investigator
    LOW DENSITY LIPOPROTEIN AND INFLAMMATION
    NIH/NIDDK R01DK036702Jul 1, 1985 - Jun 30, 1996
    Role: Principal Investigator
    LOW DENSITY LIPOPROTEINS AND GOUT
    NIH/NIADDK R23AM036702Jul 1, 1985 - Jun 30, 1988
    Role: Principal Investigator
    LOW DENSITY LIPOPROTEINS AND GOUT
    NIH/NIDDK R23DK036702Jul 1, 1985 - Jun 30, 1988
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Choi H, Neogi T, Stamp L, Dalbeth N, Terkeltaub R. Implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities (CARES) trial and associated FDA public safety alert. Arthritis Rheumatol. 2018 Jun 05. PMID: 29869840.
      View in: PubMed
    2. Bursill D, Taylor WJ, Terkeltaub R, Kuwabara M, Merriman TR, Grainger R, Pineda C, Louthrenoo W, Edwards NL, Andrés M, Vargas-Santos AB, Roddy E, Pascart T, Lin CT, Perez-Ruiz F, Tedeschi SK, Kim SC, Harrold LR, McCarthy G, Kumar N, Chapman PT, Tausche AK, Vazquez-Mellado J, Gutierrez M, Pinheiro GDRC, Richette P, Pascual E, Fisher MC, Burgos-Vargas R, Robinson PC, Singh JA, Jansen TL, Saag KG, Slot O, Uhlig T, Solomon DH, Keenan RT, Scire CA, Biernat-Kaluza E, Dehlin M, Nuki G, Schlesinger N, Janssen M, Stamp LK, Sivera F, Reginato AM, Jacobsson L, Lioté F, Ea HK, Rosenthal A, Bardin T, Choi HK, Hershfield MS, Czegley C, Choi SJ, Dalbeth N. Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions for disease elements in gout. Arthritis Care Res (Hoboken). 2018 May 25. PMID: 29799677.
      View in: PubMed
    3. Abhishek A, Neogi T, Choi H, Doherty M, Rosenthal AK, Terkeltaub R. Unmet Needs and the Path Forward in Joint Disease Associated with Calcium Pyrophosphate Crystal Deposition. Arthritis Rheumatol. 2018 Apr 02. PMID: 29609209.
      View in: PubMed
    4. Bursill D, Taylor WJ, Terkeltaub R, Dalbeth N. The nomenclature of the basic disease elements of gout: A content analysis of contemporary medical journals. Semin Arthritis Rheum. 2018 Mar 28. PMID: 29706241.
      View in: PubMed
    5. Serrano RL, Chen LY, Lotz MK, Liu-Bryan R, Terkeltaub R. Proteasomal function is impaired in human osteoarthritic chondrocytes and this can contribute to decreased SOX9 and aggrecan. Arthritis Rheumatol. 2018 Feb 18. PMID: 29457374.
      View in: PubMed
    6. Zeng C, Wei J, Terkeltaub R, Yang T, Choi HK, Wang YL, Xie DX, Hunter DJ, Zhang Y, Li H, Cui Y, Li LJ, Lei GH. Dose-response relationship between lower serum magnesium level and higher prevalence of knee chondrocalcinosis. Arthritis Res Ther. 2017 Oct 24; 19(1):236. PMID: 29065924.
      View in: PubMed
    7. Terkeltaub R. What makes gouty inflammation so variable? BMC Med. 2017 08 18; 15(1):158. PMID: 28818081.
      View in: PubMed
    8. Dalbeth N, Bardin T, Doherty M, Lioté F, Richette P, Saag KG, So AK, Stamp LK, Choi HK, Terkeltaub R. Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). Nat Rev Rheumatol. 2017 Sep; 13(9):561-568. PMID: 28794514.
      View in: PubMed
    9. Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Bhakta N, Adler S, Fung M, Storgard C, Baumgartner S, Perez-Ruiz F. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis Rheumatol. 2017 09; 69(9):1903-1913. PMID: 28597604.
      View in: PubMed
    10. Harrold LR, Etzel CJ, Gibofsky A, Kremer JM, Pillinger MH, Saag KG, Schlesinger N, Terkeltaub R, Cox V, Greenberg JD. Sex differences in gout characteristics: tailoring care for women and men. BMC Musculoskelet Disord. 2017 03 14; 18(1):108. PMID: 28292303.
      View in: PubMed
    11. Merriman T, Terkeltaub R. PPARGC1B: insight into the expression of the gouty inflammation phenotype: PPARGC1B and gouty inflammation. Rheumatology (Oxford). 2017 03 01; 56(3):323-325. PMID: 28003496.
      View in: PubMed
    12. Dalbeth N, Choi HK, Terkeltaub R. Review: Gout: A Roadmap to Approaches for Improving Global Outcomes. Arthritis Rheumatol. 2017 Jan; 69(1):22-34. PMID: 27389665.
      View in: PubMed
    13. Terkeltaub R. Emerging uricosurics for gout. Expert Rev Clin Pharmacol. 2017 Mar; 10(3):247-249. PMID: 27937050.
      View in: PubMed
    14. Miner JN, Tan PK, Hyndman D, Liu S, Iverson C, Nanavati P, Hagerty DT, Manhard K, Shen Z, Girardet JL, Yeh LT, Terkeltaub R, Quart B. Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther. 2016 Oct 12; 18(1):236. PMID: 27733209.
      View in: PubMed
    15. Miner J, Tan PK, Hyndman D, Liu S, Iverson C, Nanavati P, Hagerty DT, Manhard K, Shen Z, Girardet JL, Yeh LT, Terkeltaub R, Quart B. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther. 2016 Oct 03; 18(1):214. PMID: 27716403.
      View in: PubMed
    16. de Lautour H, Taylor WJ, Adebajo A, Alten R, Burgos-Vargas R, Chapman P, Cimmino MA, da Rocha Castelar Pinheiro G, Day R, Harrold LR, Helliwell P, Janssen M, Kerr G, Kavanaugh A, Khanna D, Khanna PP, Lin C, Louthrenoo W, McCarthy G, Vazquez-Mellado J, Mikuls TR, Neogi T, Ogdie A, Perez-Ruiz F, Schlesinger N, Ralph Schumacher H, Scirè CA, Singh JA, Sivera F, Slot O, Stamp LK, Tausche AK, Terkeltaub R, Uhlig T, van de Laar M, White D, Yamanaka H, Zeng X, Dalbeth N. Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. Arthritis Care Res (Hoboken). 2016 May; 68(5):667-72. PMID: 26414176.
      View in: PubMed
    17. Lu N, Rai SK, Terkeltaub R, Kim SC, Menendez ME, Choi HK. Racial disparities in the risk of Stevens-Johnson Syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the United States. Semin Arthritis Rheum. 2016 10; 46(2):253-8. PMID: 27217070; PMCID: PMC5035554 [Available on 10/01/17].
    18. Haslberger A, Terkeltaub R. Editorial: Can GPR43 Sensing of Short-Chain Fatty Acids Unchain Inflammasome-Driven Arthritis? Arthritis Rheumatol. 2015 Jun; 67(6):1419-23. PMID: 25914362; PMCID: PMC4446232.
    19. Wang Y, Zhao X, Lotz M, Terkeltaub R, Liu-Bryan R. Mitochondrial biogenesis is impaired in osteoarthritis chondrocytes but reversible via peroxisome proliferator-activated receptor ? coactivator 1a. Arthritis Rheumatol. 2015 May; 67(8):2141-53. PMID: 25940958; PMCID: PMC4519411.
    20. Zhao X, Petursson F, Viollet B, Lotz M, Terkeltaub R, Liu-Bryan R. Peroxisome proliferator-activated receptor ? coactivator 1a and FoxO3A mediate chondroprotection by AMP-activated protein kinase. Arthritis Rheumatol. 2014 Nov; 66(11):3073-82. PMID: 25047750; PMCID: PMC4343036.
    21. Wang Y, Viollet B, Terkeltaub R, Liu-Bryan R. AMP-activated protein kinase suppresses urate crystal-induced inflammation and transduces colchicine effects in macrophages. Ann Rheum Dis. 2016 Jan; 75(1):286-94. PMID: 25362043.
      View in: PubMed
    22. Liu-Bryan R, Terkeltaub R. Emerging regulators of the inflammatory process in osteoarthritis. Nat Rev Rheumatol. 2015 Jan; 11(1):35-44. PMID: 25266449; PMCID: PMC4374654.
    23. Terkeltaub R. Apolipoprotein a-I at the interface of vascular inflammation and arthritis. Arterioscler Thromb Vasc Biol. 2014 Mar; 34(3):474-6. PMID: 24554604; PMCID: PMC3975075.
    24. Khanna PP, Gladue HS, Singh MK, FitzGerald JD, Bae S, Prakash S, Kaldas M, Gogia M, Berrocal V, Townsend W, Terkeltaub R, Khanna D. Treatment of acute gout: a systematic review. Semin Arthritis Rheum. 2014 Aug; 44(1):31-8. PMID: 24650777.
      View in: PubMed
    25. Serrano RL, Yu W, Terkeltaub R. Mono-allelic and bi-allelic ENPP1 deficiency promote post-injury neointimal hyperplasia associated with increased C/EBP homologous protein expression. Atherosclerosis. 2014 Apr; 233(2):493-502. PMID: 24530784; PMCID: PMC4386864.
    26. Terkeltaub R. Gout: multinational gout guidelines: how do we move beyond 'déjà vu'? Nat Rev Rheumatol. 2013 Oct; 9(10):567-9. PMID: 24045709.
      View in: PubMed
    27. Petursson F, Husa M, June R, Lotz M, Terkeltaub R, Liu-Bryan R. Linked decreases in liver kinase B1 and AMP-activated protein kinase activity modulate matrix catabolic responses to biomechanical injury in chondrocytes. Arthritis Res Ther. 2013 Jul 25; 15(4):R77. PMID: 23883619; PMCID: PMC3979085.
    28. Terkeltaub R. Are cherries now ripe for use as a complementary therapeutic in gout? Appraisal of the state of evidence. Evid Based Med. 2013 Dec; 18(6):230-1. PMID: 23416419.
      View in: PubMed
    29. Prowse RL, Dalbeth N, Kavanaugh A, Adebajo AO, Gaffo AL, Terkeltaub R, Mandell BF, Suryana BP, Goldenstein-Schainberg C, Diaz-Torne C, Khanna D, Lioté F, Mccarthy G, Kerr GS, Yamanaka H, Janssens H, Baraf HF, Chen JH, Vazquez-Mellado J, Harrold LR, Stamp LK, Van De Laar MA, Janssen M, Doherty M, Boers M, Edwards NL, Gow P, Chapman P, Khanna P, Helliwell PS, Grainger R, Schumacher HR, Neogi T, Jansen TL, Louthrenoo W, Sivera F, Taylor WJ, Alten R. A delphi exercise to identify characteristic features of gout - opinions from patients and physicians, the first stage in developing new classification criteria. J Rheumatol. 2013 Apr; 40(4):498-505. PMID: 23418379.
      View in: PubMed
    30. Terkeltaub R, Schumacher HR, Carter JD, Baraf HS, Evans RR, Wang J, King-Davis S, Weinstein SP. Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther. 2013 Feb 01; 15(1):R25. PMID: 23375025; PMCID: PMC3672764.
    31. Husa M, Petursson F, Lotz M, Terkeltaub R, Liu-Bryan R. C/EBP homologous protein drives pro-catabolic responses in chondrocytes. Arthritis Res Ther. 2013; 15(6):R218. PMID: 24351550; PMCID: PMC3978428.
    32. Terkeltaub R. Imaging joints for calcium pyrophosphate crystal deposition: a knock to the knees. Arthritis Res Ther. 2012 Dec 27; 14(6):128. PMID: 23270654; PMCID: PMC3674586.
    33. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Lioté F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012 Oct; 64(10):1431-46. PMID: 23024028; PMCID: PMC3683400.
    34. Schumacher HR, Evans RR, Saag KG, Clower J, Jennings W, Weinstein SP, Yancopoulos GD, Wang J, Terkeltaub R. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken). 2012 Oct; 64(10):1462-70. PMID: 22549879.
      View in: PubMed
    35. Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Lioté F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012 Oct; 64(10):1447-61. PMID: 23024029; PMCID: PMC3662546.
    36. Liu-Bryan R, Terkeltaub R. The growing array of innate inflammatory ignition switches in osteoarthritis. Arthritis Rheum. 2012 Jul; 64(7):2055-8. PMID: 22488656; PMCID: PMC3711830.
    37. Dammanahalli KJ, Stevens S, Terkeltaub R. Vanin-1 pantetheinase drives smooth muscle cell activation in post-arterial injury neointimal hyperplasia. PLoS One. 2012; 7(6):e39106. PMID: 22720042; PMCID: PMC3374784.
    38. Gruber BL, Couto AR, Armas JB, Brown MA, Finzel K, Terkeltaub R. Novel ANKH amino terminus mutation (Pro5Ser) associated with early-onset calcium pyrophosphate disease with associated phosphaturia. J Clin Rheumatol. 2012 Jun; 18(4):192-5. PMID: 22647861; PMCID: PMC4362680.
    39. Yu W, Liu-Bryan R, Stevens S, Damanahalli JK, Terkeltaub R. RAGE signaling mediates post-injury arterial neointima formation by suppression of liver kinase B1 and AMPK activity. Atherosclerosis. 2012 Jun; 222(2):417-25. PMID: 22552116; PMCID: PMC3361645.
    40. Schumacher HR, Sundy JS, Terkeltaub R, Knapp HR, Mellis SJ, Stahl N, Yancopoulos GD, Soo Y, King-Davis S, Weinstein SP, Radin AR. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2012 Mar; 64(3):876-84. PMID: 22223180.
      View in: PubMed
    41. Neogi T, George J, Rekhraj S, Struthers AD, Choi H, Terkeltaub R. Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal. Arthritis Rheum. 2012 Feb; 64(2):327-38. PMID: 21953377; PMCID: PMC3265683.
    42. Nitschke Y, Baujat G, Botschen U, Wittkampf T, du Moulin M, Stella J, Le Merrer M, Guest G, Lambot K, Tazarourte-Pinturier MF, Chassaing N, Roche O, Feenstra I, Loechner K, Deshpande C, Garber SJ, Chikarmane R, Steinmann B, Shahinyan T, Martorell L, Davies J, Smith WE, Kahler SG, McCulloch M, Wraige E, Loidi L, Höhne W, Martin L, Hadj-Rabia S, Terkeltaub R, Rutsch F. Generalized arterial calcification of infancy and pseudoxanthoma elasticum can be caused by mutations in either ENPP1 or ABCC6. Am J Hum Genet. 2012 Jan 13; 90(1):25-39. PMID: 22209248; PMCID: PMC3257960.
    43. Nitschke Y, Weissen-Plenz G, Terkeltaub R, Rutsch F. Npp1 promotes atherosclerosis in ApoE knockout mice. J Cell Mol Med. 2011 Nov; 15(11):2273-83. PMID: 21477221; PMCID: PMC3154990.
    44. Rutsch F, Nitschke Y, Terkeltaub R. Genetics in arterial calcification: pieces of a puzzle and cogs in a wheel. Circ Res. 2011 Aug 19; 109(5):578-92. PMID: 21852556; PMCID: PMC3248761.
    45. Terkeltaub R, Furst DE, Digiacinto JL, Kook KA, Davis MW. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011 Aug; 63(8):2226-37. PMID: 21480191.
      View in: PubMed
    46. Terkeltaub R, Yang B, Lotz M, Liu-Bryan R. Chondrocyte AMP-activated protein kinase activity suppresses matrix degradation responses to proinflammatory cytokines interleukin-1ß and tumor necrosis factor a. Arthritis Rheum. 2011 Jul; 63(7):1928-37. PMID: 21400477; PMCID: PMC3128233.
    47. Khanna D, Sarkin AJ, Khanna PP, Shieh MM, Kavanaugh AF, Terkeltaub R, Lee SJ, Singh JA, Hirsch JD. Minimally important differences of the gout impact scale in a randomized controlled trial. Rheumatology (Oxford). 2011 Jul; 50(7):1331-6. PMID: 21372003; PMCID: PMC3307519.
    48. Cecil DL, Terkeltaub R. Arterial calcification is driven by RAGE in Enpp1-/- mice. J Vasc Res. 2011; 48(3):227-35. PMID: 21099228; PMCID: PMC2997448.
    49. Neogi T, Terkeltaub R, Ellison RC, Hunt S, Zhang Y. Serum urate is not associated with coronary artery calcification: the NHLBI Family Heart Study. J Rheumatol. 2011 Jan; 38(1):111-7. PMID: 20889594; PMCID: PMC3119360.
    50. Sarkin AJ, Levack AE, Shieh MM, Kavanaugh AF, Khanna D, Singh JA, Terkeltaub R, Lee SJ, Hirsch JD. Predictors of doctor-rated and patient-rated gout severity: gout impact scales improve assessment. J Eval Clin Pract. 2010 Dec; 16(6):1244-7. PMID: 20722884.
      View in: PubMed
    51. Lotz MK, Otsuki S, Grogan SP, Sah R, Terkeltaub R, D'Lima D. Cartilage cell clusters. Arthritis Rheum. 2010 Aug; 62(8):2206-18. PMID: 20506158.
      View in: PubMed
    52. Liu-Bryan R, Terkeltaub R. Chondrocyte innate immune myeloid differentiation factor 88-dependent signaling drives procatabolic effects of the endogenous Toll-like receptor 2/Toll-like receptor 4 ligands low molecular weight hyaluronan and high mobility group box chromosomal protein 1 in mice. Arthritis Rheum. 2010 Jul; 62(7):2004-12. PMID: 20506365; PMCID: PMC2902571.
    53. Husa M, Liu-Bryan R, Terkeltaub R. Shifting HIFs in osteoarthritis. Nat Med. 2010 Jun; 16(6):641-4. PMID: 20526316; PMCID: PMC2917906.
    54. Terkeltaub R, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010 Apr; 62(4):1060-8. PMID: 20131255.
      View in: PubMed
    55. Hirsch JD, Terkeltaub R, Khanna D, Singh J, Sarkin A, Shieh M, Kavanaugh A, Lee SJ. Gout disease-specific quality of life and the association with gout characteristics. Patient Relat Outcome Meas. 2010 Mar 01; 2010:1-8. PMID: 21686040.
      View in: PubMed
    56. Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol. 2010 Jan; 6(1):30-8. PMID: 20046204.
      View in: PubMed
    57. Polewski MD, Johnson KA, Foster M, Millán JL, Terkeltaub R. Inorganic pyrophosphatase induces type I collagen in osteoblasts. Bone. 2010 Jan; 46(1):81-90. PMID: 19733704; PMCID: PMC2818162.
    58. Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, Wu R, Mellis S, Radin A. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis. 2009 Oct; 68(10):1613-7. PMID: 19635719; PMCID: PMC2732898.
    59. Terkeltaub R. Gout. Novel therapies for treatment of gout and hyperuricemia. Arthritis Res Ther. 2009; 11(4):236. PMID: 19664185; PMCID: PMC2745774.
    60. Terkeltaub R, Zelman D, Scavulli J, Perez-Ruiz F, Lioté F. Gout Study Group: update on hyperuricemia and gout. Joint Bone Spine. 2009 Jul; 76(4):444-6. PMID: 19559637.
      View in: PubMed
    61. Torres R, Macdonald L, Croll SD, Reinhardt J, Dore A, Stevens S, Hylton DM, Rudge JS, Liu-Bryan R, Terkeltaub R, Yancopoulos GD, Murphy AJ. Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis. Ann Rheum Dis. 2009 Oct; 68(10):1602-8. PMID: 19528034.
      View in: PubMed
    62. Cecil DL, Appleton CT, Polewski MD, Mort JS, Schmidt AM, Bendele A, Beier F, Terkeltaub R. The pattern recognition receptor CD36 is a chondrocyte hypertrophy marker associated with suppression of catabolic responses and promotion of repair responses to inflammatory stimuli. J Immunol. 2009 Apr 15; 182(8):5024-31. PMID: 19342682; PMCID: PMC2698125.
    63. Terkeltaub R. A sugar transporter regulates serum urate levels: implications for prevention and management of hyperuricemia in gout. Curr Rheumatol Rep. 2009 Apr; 11(2):83-6. PMID: 19296879.
      View in: PubMed
    64. Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep. 2009 Apr; 11(2):135-40. PMID: 19296886.
      View in: PubMed
    65. Huebner JL, Johnson KA, Kraus VB, Terkeltaub R. Transglutaminase 2 is a marker of chondrocyte hypertrophy and osteoarthritis severity in the Hartley guinea pig model of knee OA. Osteoarthritis Cartilage. 2009 Aug; 17(8):1056-64. PMID: 19328881; PMCID: PMC3249463.
    66. Lee SJ, Hirsch JD, Terkeltaub R, Khanna D, Singh JA, Sarkin A, Kavanaugh A. Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford). 2009 May; 48(5):582-6. PMID: 19307257; PMCID: PMC2722803.
    67. Neogi T, Ellison RC, Hunt S, Terkeltaub R, Felson DT, Zhang Y. Serum uric acid is associated with carotid plaques: the National Heart, Lung, and Blood Institute Family Heart Study. J Rheumatol. 2009 Feb; 36(2):378-84. PMID: 19012359; PMCID: PMC2731484.
    68. Terkeltaub R. Macrophage glucocorticoid receptors join the intercellular dialogue in atherosclerotic lesion calcification. Arterioscler Thromb Vasc Biol. 2008 Dec; 28(12):2096-8. PMID: 19020314; PMCID: PMC2746738.
    69. Rutsch F, Böyer P, Nitschke Y, Ruf N, Lorenz-Depierieux B, Wittkampf T, Weissen-Plenz G, Fischer RJ, Mughal Z, Gregory JW, Davies JH, Loirat C, Strom TM, Schnabel D, Nürnberg P, Terkeltaub R. Hypophosphatemia, hyperphosphaturia, and bisphosphonate treatment are associated with survival beyond infancy in generalized arterial calcification of infancy. Circ Cardiovasc Genet. 2008 Dec; 1(2):133-40. PMID: 20016754; PMCID: PMC2794045.
    70. Terkeltaub R. Colchicine update: 2008. Semin Arthritis Rheum. 2009 Jun; 38(6):411-9. PMID: 18973929.
      View in: PubMed
    71. Hirsch JD, Lee SJ, Terkeltaub R, Khanna D, Singh J, Sarkin A, Harvey J, Kavanaugh A. Evaluation of an instrument assessing influence of Gout on health-related quality of life. J Rheumatol. 2008 Dec; 35(12):2406-14. PMID: 18925685.
      View in: PubMed
    72. Cecil DL, Terkeltaub R. Transamidation by transglutaminase 2 transforms S100A11 calgranulin into a procatabolic cytokine for chondrocytes. J Immunol. 2008 Jun 15; 180(12):8378-85. PMID: 18523305; PMCID: PMC2577366.
    73. Johnson KA, Rose DM, Terkeltaub R. Factor XIIIA mobilizes transglutaminase 2 to induce chondrocyte hypertrophic differentiation. J Cell Sci. 2008 Jul 01; 121(Pt 13):2256-64. PMID: 18544639; PMCID: PMC2615675.
    74. Millán JL, Narisawa S, Lemire I, Loisel TP, Boileau G, Leonard P, Gramatikova S, Terkeltaub R, Camacho NP, McKee MD, Crine P, Whyte MP. Enzyme replacement therapy for murine hypophosphatasia. J Bone Miner Res. 2008 Jun; 23(6):777-87. PMID: 18086009; PMCID: PMC2652241.
    75. Johnson KA, Polewski M, Terkeltaub R. Transglutaminase 2 is central to induction of the arterial calcification program by smooth muscle cells. Circ Res. 2008 Mar 14; 102(5):529-37. PMID: 18202319; PMCID: PMC2652242.
    76. Johnson KA, Yao W, Lane NE, Naquet P, Terkeltaub R. Vanin-1 pantetheinase drives increased chondrogenic potential of mesenchymal precursors in ank/ank mice. Am J Pathol. 2008 Feb; 172(2):440-53. PMID: 18187567; PMCID: PMC2312367.
    77. Terkeltaub R. Learning how and when to employ uricase as bridge therapy in refractory gout. J Rheumatol. 2007 Oct; 34(10):1955-8. PMID: 17924606.
      View in: PubMed
    78. Hough TA, Polewski M, Johnson K, Cheeseman M, Nolan PM, Vizor L, Rastan S, Boyde A, Pritzker K, Hunter AJ, Fisher EM, Terkeltaub R, Brown SD. Novel mouse model of autosomal semidominant adult hypophosphatasia has a splice site mutation in the tissue nonspecific alkaline phosphatase gene Akp2. J Bone Miner Res. 2007 Sep; 22(9):1397-407. PMID: 17539739.
      View in: PubMed
    79. Hennigan S, Terkeltaub R. Last call for alcohol in gout? Curr Rheumatol Rep. 2007 Jun; 9(3):229-30. PMID: 17531176.
      View in: PubMed
    80. Strnad P, Harada M, Siegel M, Terkeltaub R, Graham RM, Khosla C, Omary MB. Transglutaminase 2 regulates mallory body inclusion formation and injury-associated liver enlargement. Gastroenterology. 2007 Apr; 132(4):1515-26. PMID: 17408647.
      View in: PubMed
    81. Mitsuyama H, Healey RM, Terkeltaub R, Coutts RD, Amiel D. Calcification of human articular knee cartilage is primarily an effect of aging rather than osteoarthritis. Osteoarthritis Cartilage. 2007 May; 15(5):559-65. PMID: 17276093; PMCID: PMC2707182.
    82. Scott P, Ma H, Viriyakosol S, Terkeltaub R, Liu-Bryan R. Engagement of CD14 mediates the inflammatory potential of monosodium urate crystals. J Immunol. 2006 Nov 01; 177(9):6370-8. PMID: 17056568.
      View in: PubMed
    83. Zhang Y, Terkeltaub R, Nevitt M, Xu L, Neogi T, Aliabadi P, Niu J, Felson DT. Lower prevalence of chondrocalcinosis in Chinese subjects in Beijing than in white subjects in the United States: the Beijing Osteoarthritis Study. Arthritis Rheum. 2006 Nov; 54(11):3508-12. PMID: 17075853.
      View in: PubMed
    84. Rose DM, Sydlaske AD, Agha-Babakhani A, Johnson K, Terkeltaub R. Transglutaminase 2 limits murine peritoneal acute gout-like inflammation by regulating macrophage clearance of apoptotic neutrophils. Arthritis Rheum. 2006 Oct; 54(10):3363-71. PMID: 17009310.
      View in: PubMed
    85. Harmey D, Johnson KA, Zelken J, Camacho NP, Hoylaerts MF, Noda M, Terkeltaub R, Millán JL. Elevated skeletal osteopontin levels contribute to the hypophosphatasia phenotype in Akp2(-/-) mice. J Bone Miner Res. 2006 Sep; 21(9):1377-86. PMID: 16939396.
      View in: PubMed
    86. Terkeltaub R. Physiologic and pathologic functions of the NPP nucleotide pyrophosphatase/phosphodiesterase family focusing on NPP1 in calcification. Purinergic Signal. 2006 Jun; 2(2):371-7. PMID: 18404477; PMCID: PMC2254483.
    87. Lee SJ, Terkeltaub R. New developments in clinically relevant mechanisms and treatment of hyperuricemia. Curr Rheumatol Rep. 2006 Jun; 8(3):224-30. PMID: 16901081.
      View in: PubMed
    88. Terkeltaub R, Bushinsky DA, Becker MA. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther. 2006; 8 Suppl 1:S4. PMID: 16820043; PMCID: PMC3226109.
    89. Cronstein BN, Terkeltaub R. The inflammatory process of gout and its treatment. Arthritis Res Ther. 2006; 8 Suppl 1:S3. PMID: 16820042; PMCID: PMC3226108.
    90. Boisvert WA, Rose DM, Johnson KA, Fuentes ME, Lira SA, Curtiss LK, Terkeltaub R. Up-regulated expression of the CXCR2 ligand KC/GRO-alpha in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression. Am J Pathol. 2006 Apr; 168(4):1385-95. PMID: 16565511; PMCID: PMC1606562.
    91. Neogi T, Booth SL, Zhang YQ, Jacques PF, Terkeltaub R, Aliabadi P, Felson DT. Low vitamin K status is associated with osteoarthritis in the hand and knee. Arthritis Rheum. 2006 Apr; 54(4):1255-61. PMID: 16572460.
      View in: PubMed
    92. Lee SJ, Terkeltaub R, Kavanaugh A. Recent developments in diet and gout. Curr Opin Rheumatol. 2006 Mar; 18(2):193-8. PMID: 16462528.
      View in: PubMed
    93. Terkeltaub R. Hyperuricemia treatment: is creatinine clearance a safer allopurinol dosing meter than plasma creatinine levels? Nat Clin Pract Rheumatol. 2006 Feb; 2(2):68-9. PMID: 16932657.
      View in: PubMed
    94. Liu-Bryan R, Terkeltaub R. Evil humors take their toll as innate immunity makes gouty joints TREM-ble. Arthritis Rheum. 2006 Feb; 54(2):383-6. PMID: 16447213.
      View in: PubMed
    95. Terkeltaub R. Gout in 2006: the perfect storm. Bull NYU Hosp Jt Dis. 2006; 64(1-2):82-6. PMID: 17121496.
      View in: PubMed
    96. Cecil DL, Johnson K, Rediske J, Lotz M, Schmidt AM, Terkeltaub R. Inflammation-induced chondrocyte hypertrophy is driven by receptor for advanced glycation end products. J Immunol. 2005 Dec 15; 175(12):8296-302. PMID: 16339570.
      View in: PubMed
    97. Liu-Bryan R, Scott P, Sydlaske A, Rose DM, Terkeltaub R. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum. 2005 Sep; 52(9):2936-46. PMID: 16142712.
      View in: PubMed
    98. Anderson HC, Harmey D, Camacho NP, Garimella R, Sipe JB, Tague S, Bi X, Johnson K, Terkeltaub R, Millán JL. Sustained osteomalacia of long bones despite major improvement in other hypophosphatasia-related mineral deficits in tissue nonspecific alkaline phosphatase/nucleotide pyrophosphatase phosphodiesterase 1 double-deficient mice. Am J Pathol. 2005 Jun; 166(6):1711-20. PMID: 15920156; PMCID: PMC1602415.
    99. Wu CW, Terkeltaub R. What do epidemiologic studies tell us about hyperuricemia and cardiovascular disease and death? Curr Rheumatol Rep. 2005 Jun; 7(3):211-2. PMID: 15918997.
      View in: PubMed
    100. Wu CW, Terkeltaub R, Kalunian KC. Calcium-containing crystals and osteoarthritis: implications for the clinician. Curr Rheumatol Rep. 2005 Jun; 7(3):213-9. PMID: 15918998.
      View in: PubMed
    101. Liu-Bryan R, Pritzker K, Firestein GS, Terkeltaub R. TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation. J Immunol. 2005 Apr 15; 174(8):5016-23. PMID: 15814732.
      View in: PubMed
    102. Zhang Y, Johnson K, Russell RG, Wordsworth BP, Carr AJ, Terkeltaub R, Brown MA. Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate. Arthritis Rheum. 2005 Apr; 52(4):1110-7. PMID: 15818664.
      View in: PubMed
    103. Rutsch F, Terkeltaub R. Deficiencies of physiologic calcification inhibitors and low-grade inflammation in arterial calcification: lessons for cartilage calcification. Joint Bone Spine. 2005 Mar; 72(2):110-8. PMID: 15797489.
      View in: PubMed
    104. Johnson KA, Terkeltaub R. External GTP-bound transglutaminase 2 is a molecular switch for chondrocyte hypertrophic differentiation and calcification. J Biol Chem. 2005 Apr 15; 280(15):15004-12. PMID: 15691824.
      View in: PubMed
    105. Dong H, Maddux BA, Altomonte J, Meseck M, Accili D, Terkeltaub R, Johnson K, Youngren JF, Goldfine ID. Increased hepatic levels of the insulin receptor inhibitor, PC-1/NPP1, induce insulin resistance and glucose intolerance. Diabetes. 2005 Feb; 54(2):367-72. PMID: 15677494.
      View in: PubMed
    106. Johnson K, Terkeltaub R. Inorganic pyrophosphate (PPI) in pathologic calcification of articular cartilage. Front Biosci. 2005 Jan 01; 10:988-97. PMID: 15569637.
      View in: PubMed
    107. Cecil DL, Rose DM, Terkeltaub R, Liu-Bryan R. Role of interleukin-8 in PiT-1 expression and CXCR1-mediated inorganic phosphate uptake in chondrocytes. Arthritis Rheum. 2005 Jan; 52(1):144-54. PMID: 15641067.
      View in: PubMed
    108. Ruf N, Uhlenberg B, Terkeltaub R, Nürnberg P, Rutsch F. The mutational spectrum of ENPP1 as arising after the analysis of 23 unrelated patients with generalized arterial calcification of infancy (GACI). Hum Mutat. 2005 Jan; 25(1):98. PMID: 15605415.
      View in: PubMed
    109. Johnson K, Polewski M, van Etten D, Terkeltaub R. Chondrogenesis mediated by PPi depletion promotes spontaneous aortic calcification in NPP1-/- mice. Arterioscler Thromb Vasc Biol. 2005 Apr; 25(4):686-91. PMID: 15625282.
      View in: PubMed
    110. Tramontini N, Huber C, Liu-Bryan R, Terkeltaub R, Kilgore KS. Central role of complement membrane attack complex in monosodium urate crystal-induced neutrophilic rabbit knee synovitis. Arthritis Rheum. 2004 Aug; 50(8):2633-9. PMID: 15334478.
      View in: PubMed
    111. Bieber JD, Terkeltaub R. Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum. 2004 Aug; 50(8):2400-14. PMID: 15334451.
      View in: PubMed
    112. Bieber J, Terkeltaub R. The role of hypertension in cyclosporine-induced hyperuricemia. Curr Rheumatol Rep. 2004 Jun; 6(3):215-6. PMID: 15134600.
      View in: PubMed
    113. Harmey D, Hessle L, Narisawa S, Johnson KA, Terkeltaub R, Millán JL. Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders. Am J Pathol. 2004 Apr; 164(4):1199-209. PMID: 15039209; PMCID: PMC1615351.
    114. Johnson K, Svensson CI, Etten DV, Ghosh SS, Murphy AN, Powell HC, Terkeltaub R. Mediation of spontaneous knee osteoarthritis by progressive chondrocyte ATP depletion in Hartley guinea pigs. Arthritis Rheum. 2004 Apr; 50(4):1216-25. PMID: 15077304.
      View in: PubMed
    115. Liu R, Lioté F, Rose DM, Merz D, Terkeltaub R. Proline-rich tyrosine kinase 2 and Src kinase signaling transduce monosodium urate crystal-induced nitric oxide production and matrix metalloproteinase 3 expression in chondrocytes. Arthritis Rheum. 2004 Jan; 50(1):247-58. PMID: 14730623.
      View in: PubMed
    116. Vaingankar SM, Fitzpatrick TA, Johnson K, Goding JW, Maurice M, Terkeltaub R. Subcellular targeting and function of osteoblast nucleotide pyrophosphatase phosphodiesterase 1. Am J Physiol Cell Physiol. 2004 May; 286(5):C1177-87. PMID: 15075217.
      View in: PubMed
    117. Schraufstatter IU, Trieu K, Zhao M, Rose DM, Terkeltaub R, Burger M. IL-8-mediated cell migration in endothelial cells depends on cathepsin B activity and transactivation of the epidermal growth factor receptor. J Immunol. 2003 Dec 15; 171(12):6714-22. PMID: 14662875.
      View in: PubMed
    118. Terkeltaub R. Questions & answers. What's the difference between gout and pseudogout? Health News. 2003 Dec; 9(12):16. PMID: 14679973.
      View in: PubMed
    119. Terkeltaub R. Clinical practice. Gout. N Engl J Med. 2003 Oct 23; 349(17):1647-55. PMID: 14573737.
      View in: PubMed
    120. Merz D, Liu R, Johnson K, Terkeltaub R. IL-8/CXCL8 and growth-related oncogene alpha/CXCL1 induce chondrocyte hypertrophic differentiation. J Immunol. 2003 Oct 15; 171(8):4406-15. PMID: 14530367.
      View in: PubMed
    121. Rutsch F, Ruf N, Vaingankar S, Toliat MR, Suk A, Höhne W, Schauer G, Lehmann M, Roscioli T, Schnabel D, Epplen JT, Knisely A, Superti-Furga A, McGill J, Filippone M, Sinaiko AR, Vallance H, Hinrichs B, Smith W, Ferre M, Terkeltaub R, Nürnberg P. Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet. 2003 Aug; 34(4):379-81. PMID: 12881724.
      View in: PubMed
    122. Johnson K, Goding J, Van Etten D, Sali A, Hu SI, Farley D, Krug H, Hessle L, Millán JL, Terkeltaub R. Linked deficiencies in extracellular PP(i) and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression. J Bone Miner Res. 2003 Jun; 18(6):994-1004. PMID: 12817751.
      View in: PubMed
    123. Pay S, Terkeltaub R. Calcium pyrophosphate dihydrate and hydroxyapatite crystal deposition in the joint: new developments relevant to the clinician. Curr Rheumatol Rep. 2003 Jun; 5(3):235-43. PMID: 12744817.
      View in: PubMed
    124. Johnson K, Farley D, Hu SI, Terkeltaub R. One of two chondrocyte-expressed isoforms of cartilage intermediate-layer protein functions as an insulin-like growth factor 1 antagonist. Arthritis Rheum. 2003 May; 48(5):1302-14. PMID: 12746903.
      View in: PubMed
    125. Rutsch F, Terkeltaub R. Parallels between arterial and cartilage calcification: what understanding artery calcification can teach us about chondrocalcinosis. Curr Opin Rheumatol. 2003 May; 15(3):302-10. PMID: 12707585.
      View in: PubMed
    126. Johnson KA, van Etten D, Nanda N, Graham RM, Terkeltaub R. Distinct transglutaminase 2-independent and transglutaminase 2-dependent pathways mediate articular chondrocyte hypertrophy. J Biol Chem. 2003 May 23; 278(21):18824-32. PMID: 12606540.
      View in: PubMed
    127. Bakre MM, Zhu Y, Yin H, Burton DW, Terkeltaub R, Deftos LJ, Varner JA. Parathyroid hormone-related peptide is a naturally occurring, protein kinase A-dependent angiogenesis inhibitor. Nat Med. 2002 Sep; 8(9):995-1003. PMID: 12185361.
      View in: PubMed
    128. Hessle L, Johnson KA, Anderson HC, Narisawa S, Sali A, Goding JW, Terkeltaub R, Millan JL. Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci U S A. 2002 Jul 09; 99(14):9445-9. PMID: 12082181; PMCID: PMC123160.
    129. Terkeltaub R. Pseudogout, hypomagnesemia, and liver transplantation. Curr Rheumatol Rep. 2002 Jun; 4(3):243-4. PMID: 12010609.
      View in: PubMed
    130. Terkeltaub R. What does cartilage calcification tell us about osteoarthritis? J Rheumatol. 2002 Mar; 29(3):411-5. PMID: 11908551.
      View in: PubMed
    131. Terkeltaub R, Johnson K, Murphy A, Ghosh S. Invited review: the mitochondrion in osteoarthritis. Mitochondrion. 2002 Feb; 1(4):301-19. PMID: 16120285.
      View in: PubMed
    132. Terkeltaub R. Inorganic pyrophosphate generation and disposition in pathophysiology. Am J Physiol Cell Physiol. 2001 Jul; 281(1):C1-C11. PMID: 11401820.
      View in: PubMed
    133. Boisvert WA, Curtiss LK, Terkeltaub R. Interleukin-8 and its receptor CXCR2 in atherosclerosis. Immunol Res. 2000; 21(2-3):129-37. PMID: 10852110.
      View in: PubMed
    134. Terkeltaub R. Clinical trials review: crystal deposition diseases. Curr Rheumatol Rep. 1999 Dec; 1(2):97-100. PMID: 11123021.
      View in: PubMed
    135. Karpouzas GA, Terkeltaub R. New developments in the pathogenesis of articular cartilage calcification. Curr Rheumatol Rep. 1999 Dec; 1(2):121-7. PMID: 11123025.
      View in: PubMed
    136. Videen JS, Haseler LJ, Karpinski NC, Terkeltaub R. Noninvasive evaluation of adult onset myopathy from carnitine palmitoyl transferase II deficiency using proton magnetic resonance spectroscopy. J Rheumatol. 1999 Aug; 26(8):1757-63. PMID: 10451074.
      View in: PubMed
    137. Terkeltaub R, Boisvert WA, Curtiss LK. Chemokines and atherosclerosis. Curr Opin Lipidol. 1998 Oct; 9(5):397-405. PMID: 9812193.
      View in: PubMed
    138. Terkeltaub R, Johnson K, Rohnow D, Goomer R, Burton D, Deftos LJ. Bone morphogenetic proteins and bFGF exert opposing regulatory effects on PTHrP expression and inorganic pyrophosphate elaboration in immortalized murine endochondral hypertrophic chondrocytes (MCT cells). J Bone Miner Res. 1998 Jun; 13(6):931-41. PMID: 9626624.
      View in: PubMed
    139. Boisvert WA, Santiago R, Curtiss LK, Terkeltaub R. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest. 1998 Jan 15; 101(2):353-63. PMID: 9435307; PMCID: PMC508574.
    140. Deftos LJ, Burton DW, Baird SM, Terkeltaub R. Hypercalcemia and systemic lupus erythematosus. Arthritis Rheum. 1996 Dec; 39(12):2066-9. PMID: 8961913.
      View in: PubMed
    141. Solan JL, Deftos LJ, Goding JW, Terkeltaub R. Expression of the nucleoside triphosphate pyrophosphohydrolase PC-1 is induced by basic fibroblast growth factor (bFGF) and modulated by activation of the protein kinase A and C pathways in osteoblast-like osteosarcoma cells. J Bone Miner Res. 1996 Feb; 11(2):183-92. PMID: 8822342.
      View in: PubMed
    142. Terkeltaub R. Gout: questions that still need to be answered. Ann Rheum Dis. 1995 Feb; 54(2):79-81. PMID: 7702409; PMCID: PMC1005523.
    143. Brand K, Banka CL, Mackman N, Terkeltaub R, Fan ST, Curtiss LK. Oxidized LDL enhances lipopolysaccharide-induced tissue factor expression in human adherent monocytes. Arterioscler Thromb. 1994 May; 14(5):790-7. PMID: 8172855.
      View in: PubMed
    144. Terkeltaub R. Gout and mechanisms of crystal-induced inflammation. Curr Opin Rheumatol. 1993 Jul; 5(4):510-6. PMID: 8357747.
      View in: PubMed
    145. Terkeltaub R. What stops a gouty attack? J Rheumatol. 1992 Jan; 19(1):8-10. PMID: 1556704.
      View in: PubMed
    146. Terkeltaub R, Dyer CA, Martin J, Curtiss LK. Apolipoprotein (apo) E inhibits the capacity of monosodium urate crystals to stimulate neutrophils. Characterization of intraarticular apo E and demonstration of apo E binding to urate crystals in vivo. J Clin Invest. 1991 Jan; 87(1):20-6. PMID: 1985096; PMCID: PMC294981.
    147. Daggett RB, Haghighi P, Terkeltaub R. Nasal cocaine abuse causing an aggressive midline intranasal and pharyngeal destructive process mimicking midline reticulosis and limited Wegener's granulomatosis. J Rheumatol. 1990 Jun; 17(6):838-40. PMID: 2388208.
      View in: PubMed
    148. Terkeltaub R, Sklar LA, Mueller H. Neutrophil activation by inflammatory microcrystals of monosodium urate monohydrate utilizes pertussis toxin-insensitive and -sensitive pathways. J Immunol. 1990 Apr 01; 144(7):2719-24. PMID: 2108211.
      View in: PubMed
    149. Gardner GC, Terkeltaub R. Acute monoarthritis associated with intracellular positively birefringent Maltese cross appearing spherules. J Rheumatol. 1989 Mar; 16(3):394-6. PMID: 2542545.
      View in: PubMed
    150. Terkeltaub R, Santoro DA, Mandel G, Mandel N. Serum and plasma inhibit neutrophil stimulation by hydroxyapatite crystals. Evidence that serum alpha 2-HS glycoprotein is a potent and specific crystal-bound inhibitor. Arthritis Rheum. 1988 Sep; 31(9):1081-9. PMID: 2844196.
      View in: PubMed
    151. Terkeltaub R, Ginsberg MH. The inflammatory reaction to crystals. Rheum Dis Clin North Am. 1988 Aug; 14(2):353-64. PMID: 3051154.
      View in: PubMed
    Robert's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _